-
MFN Monitor: Europe’s Drug Launch Model Is Becoming a U.S. Pricing Risk
Written by
Traditional Global Launch Strategies Are Now Under Pressure For decades, the commercial path for innovative therapeutics followed a relatively predictable pathway. Secure FDA-approval, establish strategic pricing and a robust commercial footprint in US, and expand into Europe shortly thereafter. That framework has now come under attack due to the uncertainty related to the pricing policy debate between biopharma and the current US administration. The growing political and regulatory scrutiny surrounding Most Favored Nation (MFN) drug…
-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Written by
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues, and anticipate global launch governance pressures from the center. Call to Action Discover the strategies helping pharma and biotech leaders…
